Biomarker

生物标志物

基本信息

批准号：
10663247
负责人：
CHRISTOPHER T WHITLOW
金额：
$ 78.53万
依托单位：
WAKE FOREST UNIVERSITY HEALTH SCIENCES
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-08-15 至 2026-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10663247
关键词：
Acetoacetates Action Research Address Affect Aging Alzheimer&apos s Disease Alzheimer&apos s disease model Alzheimer&apos s disease pathology Alzheimer&apos s disease related dementia Alzheimer’s disease biomarker Amyloid beta-Protein Animal Model Animals Area Biological Markers Biometry Blood Blood Vessels Brain imaging Cerebrovascular Disorders Classification Clinical Clinical Data Clinical assessments Cognition Collection Communities Complement Consensus Consultations Cyclotrons Data Data Management Resources Data Set Dedications Dementia Development Disease Disease Progression Doctor of Philosophy Education Frequencies Future Genomics Head Image Impaired cognition Individual Infrastructure Ligands Magnetic Resonance Imaging Measures Metabolic Methods Microtubules Mission Mitochondria Modeling Nature Neurodegenerative Disorders Participant Pathologic Pathology Phase Phenotype Positron-Emission Tomography Prevention strategy Process Production Protocols documentation Race Recommendation Research Research Personnel Resolution Resources Risk Rodent Role Scientific Advances and Accomplishments Slice Spinal Puncture Standardization Synaptic Vesicles Techniques Therapeutic Intervention Tracer Training Translational Research Underrepresented Populations Vascular Diseases adjudication advanced analytics age related amyloid pathology arterial spin labeling brain health brain magnetic resonance imaging cerebrovascular cohort data management data sharing ethnic diversity experience forest health disparity image translation imaging biomarker imaging facilities imaging modality imaging program innovation lifestyle factors medical schools member mild cognitive impairment molecular imaging multimodal neuroimaging neuroimaging neuropathology next generation nonhuman primate normal aging novel novel strategies participant enrollment racial diversity radiotracer relational database serial imaging targeted treatment tau Proteins treatment response user-friendly vascular risk factor

项目摘要

Imaging Biomarker Core – Project Summary The Imaging Biomarker Core (IBC) of the Alzheimer’s Disease Research Center (ADRC) at Wake Forest School of Medicine will address a critical need to establish biomarkers that reliably differentiate Alzheimer’s disease (AD) from other conditions that affect cognition in aging. Recently, an AD research framework was developed for a biologically-based classification to enhance identification of disease mechanisms, to appropriately target therapeutic interventions, and to track therapeutic response and disease progression. Neuroimaging techniques, such as magnetic resonance imaging (MRI) to measure structural changes and positron emission tomography (PET) to track changes in pathological hallmarks such as beta-amyloid and tau, comprise a powerful approach to characterize the progressive pathology associated with cognitive decline and to differentiate AD from other dementias. To establish reliable biomarkers associated with AD and other conditions that impair cognition with aging will require a large collaborative effort and the national ADRC network is ideally suited to address this need. The Wake Forest ADRC can make unique contributions to the network. The IBC will conduct longitudinal, multimodal neuroimaging paired with phenotypic and genomic characterization of a diverse cohort of participants. The IBC will provide expertise and resources to complement the ADRC’s themes that focus on: 1) early transitions from normal aging to mild cognitive impairment (MCI) and AD; 2) the role of metabolic and vascular risk in these transitions; and 3) the nature of these relationships in persons from underrepresented groups (URGs). The first aim of the IBC will be to leverage the Clinical Core and extensive existing Wake Forest imaging infrastructure, including research- dedicated PET and MRI, cyclotron, and advanced analytic pipelines, to conduct state-of-the-art longitudinal imaging to help identify the causes of AD and develop novel strategies for prevention and treatment. As a second aim, the IBC will integrate imaging data with clinical, biomarker, and other research data to facilitate scientific discovery. The third aim will be to develop imaging methods for animal models of AD, and the final aim will be to provide training and consultation on the latest scientific advances in neuroimaging to ADRC- affiliated investigators and trainees. Through these aims, the Wake Forest ADRC IBC will further the understanding of AD pathology and its relationship to cognitive decline and will significantly enhance the Center’s contribution to the ADRC network and to investigators worldwide.

成像生物标志物核心 - 项目摘要 Wake Forest的阿尔茨海默氏病研究中心（ADRC）的成像生物标志物核心（IBC）医学院将满足建立可靠的生物标志物的迫切需求疾病（AD）来自其他影响衰老认知的疾病。为基于生物学的分类而开发的，以增强疾病机制的识别，以适当靶向治疗性介入，并跟踪梯形反应和疾病进展。神经影像学技术，例如磁共振成像（MRI），以测量结构变化和正电子发射断层扫描（PET）跟踪病理标志的变化，例如β-淀粉样蛋白和Tau，包括一种强大的方法来表征与认知下降相关的渐进病理和与其他痴呆症区分开来。损害认知因老化而损害认知的条件将协作和国家ADRC 网络非常适合解决这一需求。网络。各种参与者的表征将为IBC提供专业知识和资源汇编ADRC的重点：1）从正常衰老到轻度认知的早期过渡损害（MCI）和AD； 2）代谢和血管风险的作用 OFC的第一个目标是达到IBC的第一个目标利用临床核心和广泛的熄灭尾流森林成像基础设施，包括研究 - 专用PET和MRI，回旋子和高级分析管道，以进行最先进的纵向成像以确定AD的原因，并开发小说的投影和宝藏第二个目的，IBC将将成像数据与临床，生物标志物和其他研究数据整合在一起，以促进科学发现。 AIM将提供有关ADRC-神经影像的最新科学进步的培训和咨询。附属的调查人员和受训者通过这些目标，Wake Forest ADRC IBC将进一步了解AD病理及其与认知下降的关系，并将有意义增强中心对ADRC网络和全球调查人员的贡献。